Home » Market News » DirectorsTalk Highlights » OptiBiotix Health plc “successful launch of its SlimBiome and LP products” Stephen O’Hara, CEO
Optibiotix Health Plc

OptiBiotix Health plc “successful launch of its SlimBiome and LP products” Stephen O’Hara, CEO

Stephen O’Hara, CEO of OptiBiotix, commented: “We are extremely pleased with the very high level of interest from both national and multinational companies interested in selling our products. This has already resulted in some companies sending through draft contracts. The Company anticipates that this interest will start to generate revenues from both ingredient supply, and as a component in high value white label and branded formulations and presentations, across multiples territories. We are at the start of the commercialisation process but are really excited at the high level of interest in our products. We look forward to building commercial partnerships, market presence, and multiple revenue streams in both consumer health and pharmaceutical markets around the world.”

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes has told DirectorsTalk about the successful launch of its SlimBiome(R) and LP(LDL) (R) products at the Vitafoods Europe tradeshow in Geneva from the 9-11 of May 2017. The event provided the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. This is viewed as one of the world’s leading trade fairs for the food and drinks industry.

OptiBiotix launched the first of its range of heart health products containing LP(LDL) (R) called CholBiome and CardioBiome, and its SlimBiome(R) weight management technology. Both product types were exhibited in the New Products Zone and at Sacco’s and Nutrilinea’s stands. Sacco and Nutrilinea are OptiBiotix’s European manufacturing and formulation partners and have an extensive European network to maximise the commercial opportunity provided by these products.

Both LP(LDL) (R) and SlimBiome(R) were extremely well received with high interest in the distribution and sale of these products from partners across Europe, Japan, India, Asia, Australia and the USA. OptiBiotix’s recent appointments, Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, are leading the commercialisation and internationalisation of these products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LP(LDL) (R).


Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.